
Chinese exosome technology company formed by the reorganisation of two leading Chinese exosome businesses, Jiangsu Bergere Pharmaceutical and Shanghai Yiwei Biomedicine, and brought into Suzhou in October 2022 as a key project of the Suzhou Industrial Park, where it is based in the artificial intelligence industrial park. Focuses on early exosome based diagnosis of multiple diseases and on applying exosome technology to precise diagnosis and treatment of neurodegenerative disease, holding its own exosome isolation platform and several pipelines built on large scale multicentre clinical studies covering early blood based diagnosis of neurodegenerative disease and early diagnosis and late stage monitoring of cancer. Chairs the exosome branch of the Chinese biopharmaceutical industry chain innovation and translation consortium and has completed an A plus funding round of tens of millions of yuan.
会社プロフィールを見る
評価を残す